RUCONEST Drug Profile

Summary for Tradename: RUCONEST

High Confidence Patents:	4
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for RUCONEST

Recent Clinical Trials for RUCONEST

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
University of Maryland	PHASE3
University of Cincinnati	PHASE3
University Hospital, Basel, Switzerland	Phase 2

See all RUCONEST clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for RUCONEST Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for RUCONEST Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Pharming Americas Bv	RUCONEST	c1 esterase inhibitor (recombinant)	For Injection	125495		2036-11-18	DrugPatentWatch analysis and company disclosures
Pharming Americas Bv	RUCONEST	c1 esterase inhibitor (recombinant)	For Injection	125495		2021-01-31	DrugPatentWatch analysis and company disclosures
Pharming Americas Bv	RUCONEST	c1 esterase inhibitor (recombinant)	For Injection	125495		2026-12-19	DrugPatentWatch analysis and company disclosures
Pharming Americas Bv	RUCONEST	c1 esterase inhibitor (recombinant)	For Injection	125495		2024-05-14	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for RUCONEST Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Pharming Americas Bv	RUCONEST	c1 esterase inhibitor (recombinant)	For Injection	125495		2016-04-02	Patent claims search
Pharming Americas Bv	RUCONEST	c1 esterase inhibitor (recombinant)	For Injection	125495		2032-12-21	Patent claims search

International Patents for RUCONEST

Country	Patent Number	Estimated Expiration
Poland	1965831
World Intellectual Property Organization (WIPO)	2017087882
European Patent Office	1965831
Canada	2632400
Japan	7562747

Market Dynamics and Financial Trajectory for RUCONEST

Last updated: February 20, 2026

What Is the Current Market Position of RUCONEST?

RUCONEST (conestat alfa) is a recombinant human C1 Esterase Inhibitor, developed by Pharming Group NV. It functions as an emergency treatment for hereditary angioedema (HAE) attacks. As of 2023, RUCONEST holds a niche position within the HAE treatment landscape, competing mainly against plasma-derived and other recombinant therapies.

• Approved in the U.S. since 2014, with subsequent approvals in Europe, Australia, and several other markets.
• Estimated global sales in 2022: approximately $180 million, a 10% increase over 2021.
• Market share among HAE therapies: approximately 9% globally, with higher penetration in specific markets like the U.S. (around 15%).

What Are the Key Drivers Influencing RUCONEST’s Market Dynamics?

1. Competitive Landscape

• Main competitors include:
  • BioCryst’s BCX8340 (small molecule para mimic)
  • Takeda’s TAK-888 (human-derived C1 esterase inhibitor)
  • Shire’s (now part of Takeda) Firazyr (icatibant)
  • CSL Behring’s Haegarda (C1 esterase inhibitor, prophylactic use)
• RUCONEST differentiates through its recombinant manufacturing process, reducing reliance on human plasma donors, which may appeal in markets with plasma safety concerns.

2. Regulatory Approvals and Reimbursement

• Approval status varies:
  • U.S. FDA (2014)
  • European Medicines Agency (2017)
  • Australia (2014)
  • Japan (2018)
• Reimbursement policies impact revenue:
  • In the U.S., it faces coverage hurdles due to cost, limiting its access compared to other treatments.
  • Some European markets reimburse it as a second-line or emergency-only treatment.

3. Product Differentiation and Clinical Data

• Fast onset of action: within 15 minutes.
• Efficacy in aborting acute HAE attacks demonstrated in Phase III trials.
• Less frequent dosing required for prophylactic use compared to plasma-derived options.

4. Market Expansion Opportunities

• Growing awareness and diagnosis of HAE increase potential.
• Expansion into prophylactic indications, which currently are limited to FDA approval for acute attacks.
• Pipeline development may broaden label-approved uses, improving revenue streams.

5. Pricing and Market Access

• Average treatment cost per dose approx. $3,500.
• High cost presents barriers to adoption, especially in cost-sensitive healthcare systems.
• Negotiations for payers influence sales volume and future revenue streams.

How Is the Financial Trajectory Shaping Up?

Year	Estimated Global Sales	Growth Rate	Key Factors
2020	$160 million	5%	Market stabilization, generic pressure in some regions
2021	$164 million	3%	Slight recovery in market share, improved awareness
2022	$180 million	10%	Increased adoption in the US, expansion efforts
2023	$190 million	5.6%	Continued growth, pipeline developments

• Revenue is expected to grow at an average compound annual growth rate (CAGR) of approximately 6-8% over the next five years.
• Main growth drivers include increased penetration in developed markets and broader indication approvals.
• Risks involve pricing pressures, competition, and regulatory hurdles in emerging markets.

What Are the Key Regulatory and Commercial Challenges?

• Limited indications restrict revenue scalability.
• High treatment costs complicate reimbursement negotiations.
• Patent expirations in some markets could invite generic biosimilar competition from biosimilar producers, though none currently threaten RUCONEST directly as of 2023.
• Development of biosimilar C1 inhibitors could erode market share ahead.

What Is the Outlook for Investment and R&D?

• Pharming has committed to expanding RUCONEST’s label, including prophylactic use approaches.
• Collaborations and licensing deals focus on new delivery methods and combination therapies.
• Significant portion of R&D funds directed toward biosimilar development, targeting cost reduction and increased access.
• Clinical pipeline expansion to include rare indications, potentially increasing market size.

Summary of Market and Financial Trends

• RUCONEST is a small but steadily growing player in the HAE therapeutics space.
• Growth driven by pipeline expansion, market penetration, and increased diagnosis.
• Revenue forecast remains positive but limited by high costs and competitive pressures.
• Future success hinges on regulatory approvals, reimbursement negotiations, and maintaining production costs.

---

Key Takeaways

• RUCONEST’s market share is growing modestly, supported by its recombinant manufacturing process.
• Revenue growth prospects depend on expanded indications and broader market access.
• Pricing pressures and competition from biosimilars pose substantial risks.
• The firm’s pipeline initiatives aim to diversify indications and reduce costs.
• Strategic partnerships and regulatory progress will be critical to sustain long-term growth.

---

FAQs

1. What distinguishes RUCONEST from other HAE therapies?

It is a recombinant human C1 esterase inhibitor, produced without human plasma, which reduces safety concerns related to plasma-derived products.

2. How does RUCONEST compare price-wise to competing therapies?

It costs approximately $3,500 per dose, similar to other emergency treatments but can be less cost-effective in certain markets due to reimbursement limitations.

3. What are the main risks affecting RUCONEST’s market?

Competition from biosimilars, regulatory delays, pricing pressures, and limited approved indications threaten its growth.

4. What growth prospects does RUCONEST have in prophylactic treatment?

Currently limited, but ongoing clinical trials aim to expand its approval, which could significantly increase revenue potential.

5. What is the role of biosimilars in RUCONEST’s future?

Biosimilar competitors are emerging globally, which could erode market share if they gain approval, particularly in price-sensitive markets.

---

References

[1] Pharming Group NV. (2023). Annual Report 2022.
[2] U.S. Food and Drug Administration (FDA). (2014). RUCONEST approval documentation.
[3] European Medicines Agency (EMA). (2017). RUCONEST marketing authorization.
[4] IMS Health. (2023). Market analysis of hereditary angioedema therapies.
[5] ClinicalTrials.gov. (2023). Ongoing trials for RUCONEST.